The organic cation transporter-3 is a pivotal modulator of neurodegeneration in the nigrostriatal dopaminergic pathway

Toxic organic cations can damage nigrostriatal dopaminergic pathways as seen in most parkinsonian syndromes and in some cases of illicit drug exposure. Here, we show that the organic cation transporter 3 (Oct3) is expressed in nondopaminergic cells adjacent to both the soma and terminals of midbrain dopaminergic neurons. We hypothesized that Oct3 contributes to the dopaminergic damage by bidirectionally regulating the local bioavailability of toxic species. Consistent with this view, Oct3 deletion and pharmacological inhibition hampers the release of the toxic organic cation 1-methyl-4-phenylpyridinium from astrocytes and protects against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurodegeneration in mice. Furthermore, Oct3 deletion impairs the removal of the excess extracellular dopamine induced by methamphetamine and enhances striatal dopaminergic terminal damage caused by this psychostimulant. These results may have far-reaching implications for our understanding of the mechanism of cell death in a wide range of neurodegenerative diseases and may open new avenues for neuroprotective intervention.

[1]  J. Bowyer,et al.  Time Course of Brain Temperature and Caudate/Putamen Microdialysate Levels of Amphetamine and Dopamine in Rats after Multiple Doses of d‐Amphetamine , 1999, Annals of the New York Academy of Sciences.

[2]  D. Barlow,et al.  Impaired Activity of the Extraneuronal Monoamine Transporter System Known as Uptake-2 inOrct3/Slc22a3-Deficient Mice , 2001, Molecular and Cellular Biology.

[3]  J. Cano,et al.  Validity of a quantitative technique to study striatal dopaminergic neurodegeneration by in vivo microdialysis , 2001, Journal of Neuroscience Methods.

[4]  C. Lowry,et al.  Distribution of organic cation transporter 3, a corticosterone‐sensitive monoamine transporter, in the rat brain , 2009, The Journal of comparative neurology.

[5]  Hynek Wichterle,et al.  Astrocytes expressing ALS-linked mutated SOD1 release factors selectively toxic to motor neurons , 2007, Nature Neuroscience.

[6]  Ji-Yeon Shin,et al.  Expression of mutant huntingtin in glial cells contributes to neuronal excitotoxicity , 2005, The Journal of cell biology.

[7]  B. Giros,et al.  Altered aminergic neurotransmission in the brain of organic cation transporter 3‐deficient mice , 2008, Journal of neurochemistry.

[8]  R. Gainetdinov,et al.  Increased Methamphetamine Neurotoxicity in Heterozygous Vesicular Monoamine Transporter 2 Knock-Out Mice , 1999, The Journal of Neuroscience.

[9]  M. C. Scorza,et al.  Monoamine oxidase inhibitory properties of some methoxylated and alkylthio amphetamine derivatives: structure-activity relationships. , 1997, Biochemical pharmacology.

[10]  G. Bishop,et al.  Increased expression of the glial glutamate transporter EAAT2 modulates excitotoxicity and delays the onset but not the outcome of ALS in mice. , 2003, Human molecular genetics.

[11]  Saumya Das,et al.  Expression of the Alzheimer amyloid-promoting factor antichymotrypsin is induced in human astrocytes by IL-1 , 1995, Neuron.

[12]  G. Rappold,et al.  Molecular identification of the corticosterone-sensitive extraneuronal catecholamine transporter , 1998, Nature Neuroscience.

[13]  J. Rothstein,et al.  Focal Transplantation-based Astrocyte Replacement is Neuroprotective in a Model of Motor Neuron Disease , 2008, Nature Neuroscience.

[14]  J. Cadet,et al.  Neurotoxicity of substituted amphetamines: Molecular and cellular mechanisms , 2007, Neurotoxicity Research.

[15]  R. Gainetdinov,et al.  Role of Dopamine Transporter in Methamphetamine-Induced Neurotoxicity: Evidence from Mice Lacking the Transporter , 1998, The Journal of Neuroscience.

[16]  Robert Burke,et al.  Resistance of α-synuclein null mice to the parkinsonian neurotoxin MPTP , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[17]  C D Marsden,et al.  Isoquinoline derivatives as endogenous neurotoxins in the aetiology of Parkinson's disease. , 1998, Biochemical pharmacology.

[18]  W. Dauer,et al.  Parkinson's Disease Mechanisms and Models , 2003, Neuron.

[19]  V. Ganapathy,et al.  Identity of the Organic Cation Transporter OCT3 as the Extraneuronal Monoamine Transporter (uptake2) and Evidence for the Expression of the Transporter in the Brain* , 1998, The Journal of Biological Chemistry.

[20]  S. Przedborski.  Neuroinflammation and Parkinson's disease. , 2007, Handbook of clinical neurology.

[21]  A. Spada,et al.  Bergmann glia expression of polyglutamine-expanded ataxin-7 produces neurodegeneration by impairing glutamate transport , 2006, Nature Neuroscience.

[22]  A. Levey,et al.  Dopamine transporters and neuronal injury. , 1999, Trends in pharmacological sciences.

[23]  D. Segal,et al.  Amphetamine and its analogs : psychopharmacology, toxicology, and abuse , 1994 .

[24]  D. Kuhn,et al.  The newly synthesized pool of dopamine determines the severity of methamphetamine‐induced neurotoxicity , 2008, Journal of neurochemistry.

[25]  D. Sulzer,et al.  Amphetamine redistributes dopamine from synaptic vesicles to the cytosol and promotes reverse transport , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[26]  M. Iyo,et al.  Association between gene polymorphisms of SLC22A3 and methamphetamine use disorder. , 2006, Alcoholism, clinical and experimental research.

[27]  V. Ganapathy,et al.  Cloning and Functional Characterization of a Potential-sensitive, Polyspecific Organic Cation Transporter (OCT3) Most Abundantly Expressed in Placenta* , 1998, The Journal of Biological Chemistry.

[28]  P. Sonsalla,et al.  Correlation between the neostriatal content of the 1-methyl-4-phenylpyridinium species and dopaminergic neurotoxicity following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration to several strains of mice. , 1991, The Journal of pharmacology and experimental therapeutics.

[29]  D. Gründemann,et al.  Genetic variability of the extraneuronal monoamine transporter EMT (SLC22A3) , 2003, Journal of Human Genetics.

[30]  K. Matsubara,et al.  Differences in dopamine efflux induced by MPP+ and beta-carbolinium in the striatum of conscious rats. , 1996, European journal of pharmacology.

[31]  B. Giros,et al.  Differential pharmacological in vitro properties of organic cation transporters and regional distribution in rat brain , 2006, Neuropharmacology.

[32]  D. Sulzer,et al.  Methamphetamine neurotoxicity involves vacuolation of endocytic organelles and dopamine-dependent intracellular oxidative stress , 1994, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[33]  T. Herraiz,et al.  N-methyltetrahydro-beta-carboline analogs of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxin are oxidized to neurotoxic beta-carbolinium cations by heme peroxidases. , 2007, Biochemical and biophysical research communications.

[34]  G. Ricaurte,et al.  Inhibitors of Na+/H+ and Na+/Ca2+ exchange potentiate methamphetamine‐induced dopamine neurotoxicity: possible role of ionic dysregulation in methamphetamine neurotoxicity , 2001, Journal of neurochemistry.

[35]  W. Kuhr,et al.  MPP+-induced efflux of dopamine and lactate from rat striatum have similar time courses as shown by in vivo brain dialysis. , 1988, The Journal of pharmacology and experimental therapeutics.

[36]  K. Shimada,et al.  Methamphetamine-induced striatal dopamine release, behavior changes and neurotoxicity in BALB/c mice , 2000, International Journal of Developmental Neuroscience.

[37]  E. Schömig,et al.  Cyanine-related compounds: a novel class of potent inhibitors of extraneuronal noradrenaline transport , 1993, Naunyn-Schmiedeberg's Archives of Pharmacology.

[38]  E. Neafsey,et al.  Mitochondrial respiratory inhibition by N-methylated beta-carboline derivatives structurally resembling N-methyl-4-phenylpyridine. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[39]  S. Snyder,et al.  Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6 -tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[40]  E. Neafsey,et al.  Methyl-β-carbolinium analogs of MPP+ cause nigrostriatal toxicity after substantia nigra injections in rats , 1995, Brain Research.

[41]  B. Giros,et al.  Organic Cation Transporter 3 (Slc22a3) Is Implicated in Salt-Intake Regulation , 2004, The Journal of Neuroscience.

[42]  Subramaniam Pennathur,et al.  Ablation of the Inflammatory Enzyme Myeloperoxidase Mitigates Features of Parkinson's Disease in Mice , 2005, The Journal of Neuroscience.